EFFECT OF LIRAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN ELDERLY PATIENTS IN THE LEADER TRIAL

被引：4
|
作者：
Gilbert, Matthew [1 ]
Bain, Stephen [1 ]
Franek, Edward [1 ]
Jodar-Gimeno, Esteban [1 ]
Nauck, Michael [1 ]
Pratley, Richard [1 ]
Rea, Rosangela [1 ]
Saraiva, Jose [1 ]
Rasmussen, Soren [1 ]
Tornoe, Karen [1 ]
von Scholten, Bernt Johan [1 ]
Buse, John B. [1 ]
机构：
[1] Novo Nordisk AS, Soborg, Denmark
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2018年 / 71卷 / 11期
关键词：
D O I：
10.1016/S0735-1097(18)32259-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A1718
引用
收藏
页码：1718 / 1718
页数：1
相关论文
共 50 条
  • [31] Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol
    William Hinton
    Michael Feher
    Neil Munro
    Simon de Lusignan
    Diabetes Therapy, 2018, 9 : 1397 - 1402
  • [32] Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol
    Hinton, William
    Feher, Michael
    Munro, Neil
    de Lusignan, Simon
    DIABETES THERAPY, 2018, 9 (03) : 1397 - 1402
  • [33] Liraglutide and semaglutide improve cardiovascular and renal outcomes across baseline BP categories: analysis of LEADER and SUSTAIN 6
    Leiter, L. A.
    Bain, S. C.
    Bhatt, D. L.
    Buse, J. B.
    Mazer, C. D.
    Pratley, R.
    Lindberg, S.
    Rasmussen, S.
    Vrazic, H.
    Verma, S.
    DIABETOLOGIA, 2019, 62 : S364 - S365
  • [34] Targeted Maximum Likelihood Estimation (TMLE) to Estimate the Effect of Liraglutide on Cardiovascular (CV) Outcomes in Race/Ethnicity Subgroups: Post Hoc Analysis of LEADER
    Chen, David
    Abrahamsen, Trine J.
    Dang, Lauren E. E.
    Lawson, Jack
    Pratley, Richard E.
    DIABETES, 2022, 71
  • [35] Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Results From the LEADER Trial
    Mann, Johannes F. E.
    Fonseca, Vivian
    Mosenzon, Ofri
    Raz, Itamar
    Goldman, Bryan
    Idorn, Thomas
    von Scholten, Bernt Johan
    Poulter, Neil R.
    CIRCULATION, 2018, 138 (25) : 2908 - 2918
  • [36] Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Marso, Steven P.
    Daniels, Gilbert H.
    Brown-Frandsen, Kirstine
    Kristensen, Peter
    Mann, Johannes F. E.
    Nauck, Michael A.
    Nissen, Steven E.
    Pocock, Stuart
    Poulter, Neil R.
    Ravn, Lasse S.
    Steinberg, William M.
    Stockner, Mette
    Zinman, Bernard
    Bergenstal, Richard M.
    Buse, John B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 311 - 322
  • [37] Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Cohen, Scott
    Beckey, Cherylyn
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18): : 1797 - 1797
  • [38] Cardiovascular Outcomes with Dulaglutide vs. Liraglutide
    Bowe, Andy
    Poonawalla, Insiya
    Tindal, Michael
    Meah, Yunus A.
    Schwab, Phil
    DIABETES, 2020, 69
  • [39] Liraglutide Effects in Insulin-Treated Patients in LEADER
    Tack, Cornelis
    Jacob, Stephan
    Desouza, Cyrus
    Bain, Stephen C.
    Nauck, Michael A.
    Petrie, John
    Poulter, Neil R.
    Pratley, Richard E.
    Stegmann, Helen Vanya Biering Kjaer
    Bosch-Traberg, Heidrun
    Startseva, Elena
    Zinman, Bernard
    DIABETES, 2018, 67
  • [40] Liraglutide effects in insulin-treated patients in LEADER
    Tack, C.
    Jacob, S.
    Desouza, C.
    Bain, S. C.
    Nauck, M. A.
    Petrie, J.
    Poulter, N. R.
    Pratley, R. E.
    Stegmann, H. B. K.
    Bosch-Traberg, H.
    Startseva, E.
    Zinman, B.
    DIABETOLOGIA, 2018, 61 : S563 - S563
12345